Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer.
about
Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancerMirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer ModelsA review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.Selective targeting and therapy of metastatic and multidrug resistant tumors using a long circulating podophyllotoxin nanoparticle.
P2860
Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Vintafolide (EC145) for the tr ...... inum-resistant ovarian cancer.
@en
type
label
Vintafolide (EC145) for the tr ...... inum-resistant ovarian cancer.
@en
prefLabel
Vintafolide (EC145) for the tr ...... inum-resistant ovarian cancer.
@en
P2093
P2860
P1476
Vintafolide (EC145) for the tr ...... inum-resistant ovarian cancer.
@en
P2093
Allison J Ambrosio
Daphne Suzin
Edwin L Palmer
Richard T Penson
P2860
P304
P356
10.1586/17512433.2014.909723
P407
P577
2014-04-18T00:00:00Z